Novartis earnings exceeded analyst expectations in the third quarter of 2026, with non-GAAP earnings per share of $2.46, a $0.22 beat. The Swiss pharmaceutical company announced the results on October 27 and raised its full-year core operating income guidance, although revenue narrowly missed expectations and free cash flow declined.

Key Takeaways

  • Revenue rose 4.4% year over year to $14.52 billion, but missed estimates by $40 million.
  • Core operating income increased 10%, while free cash flow fell 18%.
  • The higher full-year core operating income outlook is guidance, not a completed result.

Novartis earnings show stronger profit but weaker cash flow

The quarter delivered different signals across sales, profitability and cash generation. Revenue increased from a year earlier despite falling slightly short of analyst forecasts, while non-GAAP earnings per share exceeded expectations. An earnings beat measures performance against forecasts; it does not by itself establish how much profit grew.

Core operating income increased 10%, outpacing the reported revenue growth rate. Free cash flow moved in the opposite direction, declining 18% to $5.1 billion. That divergence matters because earnings and cash available for dividends, investment and other capital commitments are different measures.

Higher operating income guidance applies to full-year 2026

Novartis raised its full-year outlook for core operating income following the quarterly results. The revision is a forward-looking management target and should be distinguished from the operating income growth already recorded in the third quarter.

The company focuses on innovative prescription medicines following the 2023 spin-off of its Sandoz generics business. Its portfolio includes treatments such as Entresto, Kisqali, Cosentyx and Kesimpta.

Dividend history provides context, not a payment guarantee

Novartis’ dividend payment history records a shareholder-approved dividend of CHF 3.70 per share for business year 2025, up 5.7%. Paid on March 12, 2026, it marked the company’s 29th consecutive annual dividend increase.

That record provides context for shareholder distributions, but it does not guarantee future increases. The third-quarter cash flow decline is a separate development from the dividend already paid for 2025.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.